BLAU FARMACÊUTICA S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.69 BRL | -6.25% |
|
+0.41% | -41.01% |
| 05-08 | Transcript : Blau Farmacêutica S.A., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-07 | Blau Farmacêutica S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,530 | 4,681 | 2,916 | 1,725 | - | - |
| Enterprise Value (EV) 1 | 5,982 | 4,317 | 3,079 | 1,920 | 2,090 | 2,221 |
| P/E ratio | 19.2 x | 12.9 x | 11.6 x | 8.64 x | 6.98 x | 5.86 x |
| Yield | 1.59% | - | - | 3.35% | 3.44% | 5.2% |
| Capitalization / Revenue | 4.78 x | 3.33 x | 2.12 x | 1.08 x | 0.96 x | 0.86 x |
| EV / Revenue | 4.38 x | 3.07 x | 2.24 x | 1.21 x | 1.16 x | 1.11 x |
| EV / EBITDA | 12.5 x | 9.11 x | 8.37 x | 5.91 x | 4.93 x | 4.39 x |
| EV / FCF | 1,035 x | 524 x | -269 x | 6.23 x | 12.4 x | -71.6 x |
| FCF Yield | 0.1% | 0.19% | -0.37% | 16% | 8.04% | -1.4% |
| Price to Book | - | 2.57 x | - | 0.81 x | 0.73 x | 0.68 x |
| Nbr of stocks (in thousands) | 179,394 | 177,831 | 177,681 | 177,681 | - | - |
| Reference price 2 | 36.40 | 26.32 | 16.41 | 9.710 | 9.710 | 9.710 |
| Announcement Date | 21/02/22 | 01/03/23 | 19/03/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,182 | 1,366 | 1,407 | 1,373 | 1,593 | 1,799 | 2,002 |
| EBITDA 1 | - | 477.5 | 474 | 368 | 325 | 423.6 | 505.9 |
| EBIT 1 | - | 456.6 | 452.2 | 329.3 | 277 | 360.3 | 429.8 |
| Operating Margin | - | 33.42% | 32.14% | 23.99% | 17.39% | 20.03% | 21.47% |
| Earnings before Tax (EBT) 1 | - | - | 468.6 | 334.2 | 286 | 342 | 410 |
| Net income 1 | - | 325.2 | 363.4 | 249.8 | 200.9 | 248.6 | 304.1 |
| Net margin | - | 23.8% | 25.83% | 18.2% | 12.62% | 13.82% | 15.19% |
| EPS 2 | 1.614 | 1.892 | 2.040 | 1.410 | 1.124 | 1.391 | 1.657 |
| Free Cash Flow 1 | - | 5.78 | 8.232 | -11.44 | 308 | 168 | -31 |
| FCF margin | - | 0.42% | 0.59% | -0.83% | 19.34% | 9.34% | -1.55% |
| FCF Conversion (EBITDA) | - | 1.21% | 1.74% | - | 94.76% | 39.66% | - |
| FCF Conversion (Net income) | - | 1.78% | 2.27% | - | 153.28% | 67.58% | - |
| Dividend per Share 2 | - | 0.5800 | - | - | 0.3250 | 0.3342 | 0.5051 |
| Announcement Date | 05/02/21 | 21/02/22 | 01/03/23 | 19/03/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 349.9 | 313.3 | 365.2 | 361.6 | 366.7 | 258.2 | 364.3 | 362.6 | 387.5 | 359.7 | 402.2 | 399.4 | 406.8 | 424.6 |
| EBITDA 1 | 91.11 | 115.4 | 120.5 | 119 | 120 | 58 | 94.15 | 163.9 | 52 | 65 | 72.8 | 94.32 | 97.54 | - |
| EBIT 1 | - | - | 115.2 | 113.1 | 113.7 | 51.28 | 86.25 | 152.3 | 39.5 | 48.84 | 61.69 | 65.79 | 70.68 | 69.71 |
| Operating Margin | - | - | 31.55% | 31.27% | 31% | 19.86% | 23.67% | 41.98% | 10.2% | 13.58% | 15.34% | 16.47% | 17.37% | 16.42% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | 38.02 | - | - | - | - | - |
| Net income | - | 61.46 | 112.4 | 94.53 | 94.98 | 51.95 | 70.79 | 99.4 | 27.68 | 40.09 | - | - | - | - |
| Net margin | - | 19.61% | 30.77% | 26.14% | 25.9% | 20.12% | 19.43% | 27.41% | 7.14% | 11.15% | - | - | - | - |
| EPS 2 | 0.2294 | - | 0.6300 | 0.4200 | 0.5308 | - | 0.4000 | 0.5600 | 0.1600 | 0.2300 | 0.2265 | 0.2695 | 0.3127 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | 0.2625 | - |
| Announcement Date | 21/02/22 | 09/05/22 | 01/08/22 | 03/11/22 | 01/03/23 | 05/05/23 | 09/08/23 | 09/11/23 | 19/03/24 | 07/05/24 | - | - | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 163 | 195 | 365 | 496 |
| Net Cash position 1 | - | 548 | 364 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 0.4429 x | 0.5992 x | 0.8615 x | 0.9798 x |
| Free Cash Flow 1 | - | 5.78 | 8.23 | -11.4 | 308 | 168 | -31 |
| ROE (net income / shareholders' equity) | - | 35% | 21% | 13.1% | 9.66% | 10.1% | 12.2% |
| ROA (Net income/ Total Assets) | - | 18.1% | 15.1% | 9% | 5.81% | 6.8% | 7.32% |
| Assets 1 | - | 1,800 | 2,414 | 2,776 | 3,460 | 3,654 | 4,156 |
| Book Value Per Share 2 | - | - | 10.20 | - | 12.10 | 13.20 | 14.30 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 148 | 180 | 232 | 102 | 214 | 330 |
| Capex / Sales | - | 10.85% | 12.8% | 16.9% | 6.4% | 11.9% | 16.48% |
| Announcement Date | 05/02/21 | 21/02/22 | 01/03/23 | 19/03/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
7
Last Close Price
9.71
BRL
Average target price
13.57
BRL
Spread / Average Target
+39.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.01% | 317M | |
| +55.29% | 815B | |
| +45.25% | 654B | |
| -6.87% | 354B | |
| +21.45% | 337B | |
| +10.33% | 302B | |
| +17.68% | 247B | |
| +2.13% | 229B | |
| +12.85% | 219B | |
| +9.59% | 171B |
- Stock Market
- Equities
- BLAU3 Stock
- Financials Blau Farmacêutica S.A.
